Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections

International Journal of Antimicrobial Agents

Volumn 42, Issue 3, 2013, Pages 250-255

  Di Paolo, Antonello ^a   Tascini, Carlo ^b   Polillo, Marialuisa ^a   Gemignani, Giulia ^b   Nielsen, Elisabet I ^c   Bocci, Guido ^a   Karlsson, Mats O ^c   Menichetti, Francesco ^b   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Daptomycin; Gram positive infections; Population pharmacokinetics

Indexed keywords

DAPTOMYCIN;

AGED; AREA UNDER THE CURVE; ARTICLE; BONE INFECTION; CARDIOVASCULAR INFECTION; CREATININE CLEARANCE; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; FEMALE; GRAM POSITIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; SEPTICEMIA; SKIN INFECTION;

DAPTOMYCIN; GRAM-POSITIVE INFECTIONS; POPULATION PHARMACOKINETICS;

AGED; ANTI-BACTERIAL AGENTS; CREATININE; DAPTOMYCIN; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS;

EID: 84883455640     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.06.006     Document Type: Article

References (30)

1. F. Menichetti Current and emerging serious Gram-positive infections Clin Microbiol Infect 11 Suppl. 3 2005 22 28
2. R. Metzger, H. Bonatti, and R. Sawyer Future trends in the treatment of serious Gram-positive infections Drugs Today (Barc) 45 2009 33 45
3. J.F. Mohr, L.V. Friederich, S. Yankelev, and K.C. Lamp Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcome Registry and Experience (CORE) Int J Antimicrob Agents 33 2009 543 548
4. N. Safdar, D. Andes, and W.A. Craig In vivo pharmacodynamic activity of daptomycin Antimicrob Agents Chemother 48 2004 63 68
5. B.H. Dvorchik, D. Brazier, M.F. DeBruin, and R.D. Arbeit Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects Antimicrob Agents Chemother 47 2003 1318 1323
6. M. Benvenuto, D.P. Benziger, S. Yankelev, and G. Vigliani Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers Antimicrob Agents Chemother 50 2006 3245 3249
7. R. Kullar, S.L. Davis, D.P. Levine, J.J. Zhao, C.W. Crank, and J. Segreti High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study Pharmacotherapy 31 2011 527 536
8. G. Wu, T. Abraham, J. Rapp, F. Vastey, N. Saad, and E. Balmir Daptomycin: evaluation of a high-dose treatment strategy Int J Antimicrob Agents 38 2011 192 196
9. S.M. Abdel-Rahman, G. Chandorkar, R.L. Akins, J.S. Bradley, R.F. Jacobs, and J. Donovan Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections Pediatr Infect Dis J 30 2011 712 714
10. C. Tascini, A. Di Paolo, M. Polillo, M. Ferrari, P. Lambelet, and R. Danesi Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin Antimicrob Agents Chemother 55 2011 2458 2459
11. M.P. Pai, J.P. Noremberg, T. Anderson, D.W. Goade, K.A. Rodvold, and R.A. Telepak Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin Antimicrob Agents Chemother 51 2007 2741 2747
12. R. Kullar, J.N. Chin, D.J. Edwards, D. Parker, W.M. Coplin, and M.J. Rybak Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections Antimicrob Agents Chemother 55 2011 3505 3509
13. C. Tascini, A. Di Paolo, R. Poletti, S. Flammini, M. Emdin, and I. Ciullo Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis Antimicrob Agents Chemother 57 2013 601 602
14. B. Dvorchik, R.D. Arbeit, J. Chung, S. Liu, W. Knebel, and H. Kastrissios Population pharmacokinetics of daptomycin Antimicrob Agents Chemother 48 2004 2799 2807
15. J.S. Bubalo, M.Y. Munar, G. Cherala, B. Hayes-Lattin, and R. Maziarz Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever Antimicrob Agents Chemother 53 2009 428 434
16. M. Polillo, C. Tascini, M. Lastella, P. Malacarne, L. Ciofi, and B. Viaggi A rapid liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma Ther Drug Monit 32 2010 200 205
17. S.L. Beal, L.B. Sheiner, and A.J. Boeckmann NONMEM users guides 1989-2009 ICON Development Solutions Ellicott City, MD
18. E.N. Jonsson, and M.O. Karlsson Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Methods Programs Biomed 58 1999 51 64
19. L. Lindbom, J. Ribbing, and E.N. Jonsson Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming Comput Methods Programs Biomed 75 2004 85 94
20. M. Bergstrand, A.C. Hooker, J.E. Wallin, and M.O. Karlsson Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models AAPS J 13 2011 143 151
21. R.M. Savic, and M.O. Karlsson Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions AAPS J 11 2009 558 569
22. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee EUCAST technical note on daptomycin Clin Microbiol Infect 12 2006 599 601
23. G. Sakoulas, J. Brown, K.C. Lamp, L.V. Friederich, and K.C. Lindfield Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience Clin Ther 31 2009 1936 1945
24. J.F. Mohr 3rd, L. Ostrosky-Zeichner, D.J. Wainright, D.H. Parks, T.C. Hollenbeck, and C.D. Ericsson Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury Antimicrob Agents Chemother 52 2008 1891 1893
25. A.M. Vilay, M. Grio, D.D. Depestel, K.M. Sowinski, L. Gao, and M. Heung Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis Crit Care Med 39 2011 19 25
26. F. Pea, P. Cojutti, R. Sbrojavacca, B. Cadeo, F. Cristini, and A. Bulfoni TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient Ann Pharmacother 45 2011 e37
27. E. Nannini, B.E. Murray, and C.A. Arias Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus Curr Opin Pharmacol 10 2010 516 521
28. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints - bacteria (v. 3.1). http://www.eucast.org/clinical- breakpoints [accessed December 2011].
29. D. Begic, C. von Eiff, and B.T. Tsuji Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype J Antimicrob Chemother 63 2009 977 981
30. S.M. Bhavnani, C.M. Rubino, P.G. Ambrose, and G.L. Drusano Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis Clin Infect Dis 50 2010 1568 1574